Long-Term Prophylactic Administration of Octreotide Reduces the Rise in Serum Amylase After Endoscopic Procedures on Vaterʼs Papilla

Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis

“…In addition, we included five studies [7,9,10,21,22] published after 2000, which were not available to them. Regarding studies of octreotide, Andriulli et al [38] included five trials [43][44][45][46][47] that we excluded. We excluded two [43,45] for non-English language and three [44,46,47] for no information on double-blindedness.…”

“…Regarding studies of octreotide, Andriulli et al [38] included five trials [43][44][45][46][47] that we excluded. We excluded two [43,45] for non-English language and three [44,46,47] for no information on double-blindedness. We included an additional four studies [15,[25][26][27] published after 1999.…”

“…In 2009, Zhang et al [30] conducted a meta-analysis including six studies [25,27,46,[49][50][51] about the preventive efficacy of octreotide for post-ERCP pancreatitis and suggested possible significant efficacy of high-dose octreotide over 0.5 mg. Their meta-analysis included three non-double-blinded RCTs [46,50,51] and one abstract [49], all of which we excluded from our meta-analysis. They excluded one study [26] in which 1000 lg of octreotide was given in five divided doses.…”

Use of the laparoscopic–endoscopic approach, the so-called “rendezvous” technique, in cholecystocholedocholithiasis

“…In the past few decades, several studies have considered different strategies to reduce the occurrence of post-ERCP pancreatitis but with uncertain results. Pharmacological prophylaxis [1,5,21,28] as well as the insertion of pancreatic stents [24] were tested. Multivariate analyses have delineated patient-and procedure-related risk factors for this complication so that post-ERCP pancreatitis is now largely predictable [11].…”

Pancreatits after endoscopic retrograde cholangio-pancreatography

“…This prophylactic approach aiming at inhibiting exocrine pancreatic secretion within the first hour after papillary manipulation did ensure a peak serum level of hormone at the time of papillary manipulation, and a subsequent subcutaneous dose was given to obtain a longer post-procedure effect. Subcutaneous injection of 0.2 mg of octreotide three times daily for three days effectively reduced both the incidence of post-ERCP hyperamylasemia and pain [99] ; however, 24-h prophylaxis using octreotide 30 min before the procedure did not reduce the incidence of pancreatitis in selected patients at high risk of PEP [5] . From 1991 up to now, all randomized clinical trials have been published with mainly disappointing results.…”